4//SEC Filing
Gonsalves Paul 4
Accession 0001209191-22-006838
CIK 0000884624other
Filed
Feb 2, 7:00 PM ET
Accepted
Feb 3, 4:51 PM ET
Size
8.0 KB
Accession
0001209191-22-006838
Insider Transaction Report
Form 4
Gonsalves Paul
President, Global Extremities
Transactions
- Award
Performance Share Units
2022-02-01+9,836→ 9,836 totalExercise: $0.00→ Common Stock (9,836 underlying) - Award
Common Stock
2022-02-01+9,836→ 26,403 total
Footnotes (2)
- [F1]Represents time-based vesting restricted stock units that vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, February 1, 2022.
- [F2]Represents performance-based vesting restricted stock units ("PSUs") that will settle as common stock on a one-for-one basis. Under the terms of the grant, the PSUs may vest based upon achieved product revenues for the 2023 fiscal year (the "Product Revenue Vesting Percentage"), as modified by a total shareholder return ("TSR") modifier (the "TSR Modifier"). The amount in the table above represents the target number of PSUs granted. The performance period of the grant is 2/1/22-1/31/25. The Product Revenue Vesting Percentage can be achieved within a range of 50% to 200% of target, based upon the level of recognized revenues. If the Product Revenue Vesting Percentage is achieved at or above the threshold level, it shall be multiplied by the TSR Modifier (ranging from 0.75 to 1.25), which shall be determined based on the Company's relative TSR during the performance period as compared to a specified peer group.
Documents
Issuer
Orthofix Medical Inc.
CIK 0000884624
Entity typeother
Related Parties
1- filerCIK 0001824319
Filing Metadata
- Form type
- 4
- Filed
- Feb 2, 7:00 PM ET
- Accepted
- Feb 3, 4:51 PM ET
- Size
- 8.0 KB